好色先生

好色先生

Explore the latest content from across our publications
Join The AAN

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Long-term Motor and Non-Motor Symptom Benefits in Patients With Advanced Parkinson’s Disease Treated With Levodopa-Carbidopa Intestinal Gel by Baseline Hoehn & Yahr Stage: Analysis of the DUOGLOBE Study
Movement Disorders
P1 - Poster Session 1 (9:00 AM-5:00 PM)
251
Evaluate the effect of baseline disease severity on long-term effectiveness and safety of levodopa-carbidopa intestinal gel (LCIG) treatment in routine clinical practice.
Real-world data on the impact of baseline disease severity on efficacy and safety of LCIG are limited.
DUOGLOBE (NCT02611713) was a prospective, multinational, observational study of LCIG-naïve patients treated in routine clinical practice and 3-year follow-up. Stratified by H&Y scores <3 and ≥3 at baseline, this post hoc analysis assessed change from baseline up to month (M) 36 for “Off” time, Unified Dyskinesia Rating Scale (UDysRS), Non-Motor Symptom Scale (NMSS), Unified Parkinson’s Disease Rating Scale (UPDRS) II and III, axial symptoms (UPDRS III axial items [sum of 18/22/27–30]), Parkinson’s disease Questionnaire 8 (PDQ-8), and serious adverse events (SAEs).
Of 188 patients with baseline H&Y scores, baseline characteristics in both groups were similar except mean (SD) UPDRS II (<3, 10.7 [6.7]; ≥3, 16.8 [7.6]) and III (<3, 19.3 [9.4]; ≥3, 31.7 [13.0]). Strong, significant improvements were observed in “Off” time through M36 in both groups (<3, P<.01; ≥3, P<.001). In <3, UDysRS total scores improved significantly until M12 (P<.05) and numerically through M36, and significantly improved through M36 (P<.05) in ≥3. Sustained improvements in NMSS were observed in both groups (both P<.05), with significant improvements in PDQ-8 until M18 (<3, P<.05; ≥3, P<.01). Both groups showed a significant increase in UPDRS II and III scores at M36 (UPDRS II <3, P<.001; ≥3, P<.05; UPDRS III <3, P<.01; ≥3, P<.05). Axial symptoms worsened in <3 (P<.001) but remained generally stable over time in ≥3. SAEs and discontinuation rates were generally similar in both groups.
This first reported long-term analysis in patients who received LCIG in different H&Y stages suggests patients experience important benefits from LCIG treatment independent of H&Y stage. Safety was consistent with the established LCIG safety profile.
Authors/Disclosures
Lars Bergmann, MD (Abbvie GmbH & Co)
PRESENTER 		Lars Bergmann has received personal compensation for serving as an employee of Abbvie. Lars Bergmann has stock in Abbvie.
No disclosure on file
No disclosure on file
Jason L. Aldred, MD, FAAN (Selkirk Neurology) Dr. Aldred has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Boston Scientific. Dr. Aldred has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Abbvie. Dr. Aldred has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Allergan . Dr. Aldred has received personal compensation in the range of $0-$499 for serving as a Consultant for Quadralynx. Dr. Aldred has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Abbvie. Dr. Aldred has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Boston Scientific. Dr. Aldred has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Medtronic. Dr. Aldred has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Abbvie. Dr. Aldred has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Acorda. Dr. Aldred has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Allergan. Dr. Aldred has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Boston Scientific. Dr. Aldred has received personal compensation in the range of $100,000-$499,999 for serving on a Speakers Bureau for TEVA. Dr. Aldred has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Medtronic. Dr. Aldred has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for US World Meds. Dr. Aldred has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Kyowa Kirin. Dr. Aldred has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Sunovion. Dr. Aldred has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Amneal. Dr. Aldred has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Biogen. Dr. Aldred has received personal compensation in the range of $50,000-$99,999 for serving as an Expert Witness for Arete Neuroscience, PLLC. The institution of Dr. Aldred has received research support from Biogen . The institution of Dr. Aldred has received research support from Abbvie. The institution of Dr. Aldred has received research support from Merz. The institution of Dr. Aldred has received research support from AstraZeneca. The institution of Dr. Aldred has received research support from Neurocrine. The institution of Dr. Aldred has received research support from Aptinyx. The institution of Dr. Aldred has received research support from Cerevance. The institution of Dr. Aldred has received research support from Boston Scientific . The institution of Dr. Aldred has received research support from Parkinson Foundation . The institution of Dr. Aldred has received research support from Roche. The institution of Dr. Aldred has received research support from Sage Therapeutics. The institution of Dr. Aldred has received research support from Annovis. The institution of Dr. Aldred has received research support from Biovie. The institution of Dr. Aldred has received research support from NeuroDerm. The institution of Dr. Aldred has received research support from PhotoPharma. The institution of Dr. Aldred has received research support from Lilly.
Paul M. Bourgeois, MD Dr. Bourgeois has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for ABBVIE.
Thomas L. Davis, MD Dr. Davis has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Abbvie. Dr. Davis has received personal compensation in the range of $10,000-$49,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Parkinson Foundation.
Esther Cubo Delgado, MD, PhD, FAAN (Fundacion Burgos Investigacion Salud CIF G09254616) Dr. Cubo Delgado has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Abbvie. Dr. Cubo Delgado has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for Zambon. Dr. Cubo Delgado has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Abbvie. The institution of Dr. Cubo Delgado has received research support from Spanish health ministry. The institution of Dr. Cubo Delgado has received research support from European union grant.
Marieta Anca-Herschkovitsch, MD (Edith Wolfson Medical Center- Holon-Israel) Marieta Anca-Herschkovitsch, MD has nothing to disclose.
No disclosure on file
Mustafa S. Siddiqui, MD, FAAN Dr. Siddiqui has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Boston Scientific Neuromodulation. Dr. Siddiqui has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Medtronic. The institution of Dr. Siddiqui has received research support from Boston Scientific Neuromodulation. The institution of Dr. Siddiqui has received research support from Abbvie. The institution of Dr. Siddiqui has received research support from National Institute of Health .
Mihaela A. Simu, MD, PhD (University of Medicine and Pharmacy Timisoara) Dr. Simu has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for Novartis PHarma . Dr. Simu has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for Sanofi Romania. Dr. Simu has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Novartis. Dr. Simu has received personal compensation in the range of $0-$499 for serving on a Speakers Bureau for ABBVIE. Dr. Simu has received personal compensation in the range of $0-$499 for serving on a Speakers Bureau for ABBVIE. Dr. Simu has received personal compensation in the range of $0-$499 for serving on a Speakers Bureau for ABBVIE. Dr. Simu has received personal compensation in the range of $0-$499 for serving on a Speakers Bureau for Merck. Dr. Simu has received personal compensation in the range of $0-$499 for serving on a Speakers Bureau for Merck. Dr. Simu has received personal compensation in the range of $0-$499 for serving on a Speakers Bureau for Merck. Dr. Simu has received personal compensation in the range of $0-$499 for serving on a Speakers Bureau for TEVA. Dr. Simu has received personal compensation in the range of $0-$499 for serving on a Speakers Bureau for Sanofi Romania. Dr. Simu has received personal compensation in the range of $0-$499 for serving on a Speakers Bureau for Sanofi Romania. Dr. Simu has received personal compensation in the range of $0-$499 for serving on a Speakers Bureau for Ipsen . Dr. Simu has received personal compensation in the range of $0-$499 for serving on a Speakers Bureau for Bayer. Dr. Simu has received personal compensation in the range of $0-$499 for serving on a Speakers Bureau for Roche. Dr. Simu has received personal compensation in the range of $0-$499 for serving on a Speakers Bureau for Merck. Dr. Simu has received personal compensation in the range of $0-$499 for serving on a Speakers Bureau for ABBVIE. Dr. Simu has received personal compensation in the range of $0-$499 for serving on a Speakers Bureau for UCB. Dr. Simu has received personal compensation in the range of $0-$499 for serving on a Speakers Bureau for Novartis Pharma. Dr. Simu has received personal compensation in the range of $0-$499 for serving on a Speakers Bureau for Ipsen. Dr. Simu has received personal compensation in the range of $0-$499 for serving on a Speakers Bureau for Johnson &Johnson. Dr. Simu has received personal compensation in the range of $0-$499 for serving on a Speakers Bureau for Roche . Dr. Simu has received personal compensation in the range of $0-$499 for serving on a Speakers Bureau for Sanofi. Dr. Simu has received personal compensation in the range of $0-$499 for serving on a Speakers Bureau for Sanofy Romania. Dr. Simu has received personal compensation in the range of $0-$499 for serving on a Speakers Bureau for ABBVIE. Dr. Simu has received personal compensation in the range of $0-$499 for serving on a Speakers Bureau for Roche. Dr. Simu has received personal compensation in the range of $0-$499 for serving on a Speakers Bureau for Sanofi Romania. Dr. Simu has received personal compensation in the range of $0-$499 for serving on a Speakers Bureau for Merck. Dr. Simu has received personal compensation in the range of $0-$499 for serving on a Speakers Bureau for Sanofi. Dr. Simu has received personal compensation in the range of $0-$499 for serving on a Speakers Bureau for Roche. Dr. Simu has received personal compensation in the range of $0-$499 for serving on a Speakers Bureau for Novartis. Dr. Simu has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Abbvie. Dr. Simu has received personal compensation in the range of $0-$499 for serving on a Speakers Bureau for Merck. Dr. Simu has received personal compensation in the range of $0-$499 for serving on a Speakers Bureau for Abbvie . Dr. Simu has received personal compensation in the range of $0-$499 for serving on a Speakers Bureau for Sanofi. Dr. Simu has received personal compensation in the range of $0-$499 for serving on a Speakers Bureau for Novartis. Dr. Simu has received personal compensation in the range of $0-$499 for serving on a Speakers Bureau for Abbvie. Dr. Simu has received personal compensation in the range of $0-$499 for serving on a Speakers Bureau for Sanofi. Dr. Simu has received personal compensation in the range of $0-$499 for serving on a Speakers Bureau for Johnson&Johnson. Dr. Simu has received personal compensation in the range of $0-$499 for serving on a Speakers Bureau for Sanofi. Dr. Simu has received personal compensation in the range of $0-$499 for serving on a Speakers Bureau for Roche. Dr. Simu has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Novartis. Dr. Simu has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Johnson & Johnson . Dr. Simu has received personal compensation in the range of $0-$499 for serving on a Speakers Bureau for Novartis. Dr. Simu has received personal compensation in the range of $0-$499 for serving on a Speakers Bureau for Abbvie. Dr. Simu has received personal compensation in the range of $0-$499 for serving on a Speakers Bureau for Sanofi. Dr. Simu has received personal compensation in the range of $0-$499 for serving on a Speakers Bureau for Sanofi. Dr. Simu has received personal compensation in the range of $0-$499 for serving on a Speakers Bureau for UCB. Dr. Simu has received personal compensation in the range of $0-$499 for serving on a Speakers Bureau for Merck. Dr. Simu has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Sanofi. Dr. Simu has received personal compensation in the range of $0-$499 for serving on a Speakers Bureau for Ewopharma A G. Dr. Simu has received personal compensation in the range of $0-$499 for serving on a Speakers Bureau for Roche. Dr. Simu has received personal compensation in the range of $0-$499 for serving on a Speakers Bureau for Ipsen. Dr. Simu has received personal compensation in the range of $0-$499 for serving on a Speakers Bureau for Novartis. Dr. Simu has received personal compensation in the range of $0-$499 for serving on a Speakers Bureau for Ipsen.
Omar Ladhani Omar Ladhani has received personal compensation for serving as an employee of AbbVie. Omar Ladhani has received stock or an ownership interest from AbbVie.
No disclosure on file
David G. Standaert, MD, PhD, FAAN (Univ of Alabama - Dept of Neurology) Dr. Standaert has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Abbvie, Inc. Dr. Standaert has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Curium. Dr. Standaert has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Alnylam. Dr. Standaert has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Biohaven. Dr. Standaert has received personal compensation in the range of $500-$4,999 for serving as a Consultant for CVS/Pharmacy. Dr. Standaert has received personal compensation in the range of $500-$4,999 for serving as a Consultant for HanAll Biopharma. Dr. Standaert has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Eli Lilly. Dr. Standaert has received personal compensation in the range of $500-$4,999 for serving as a Consultant for F. Hoffman LaRoche. Dr. Standaert has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Sanofi-Aventis. Dr. Standaert has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Theravance, Inc. Dr. Standaert has received personal compensation in the range of $10,000-$49,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for International Parkinson and Movement Disorder Society. The institution of Dr. Standaert has received research support from Abbvie, Inc. The institution of Dr. Standaert has received research support from American Parkinson Disease Association. The institution of Dr. Standaert has received research support from National Institutes of Health. The institution of Dr. Standaert has received research support from F. Hoffman LaRoche. Dr. Standaert has received publishing royalties from a publication relating to health care. Dr. Standaert has received personal compensation in the range of $500-$4,999 for serving as a Reviewer with National Institutes of Health. Dr. Standaert has a non-compensated relationship as a Chair, Scientific Advisory Board with American Parkinson Disease Association that is relevant to AAN interests or activities.
Norbert Kovacs Norbert Kovacs has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Boston Scientific. Norbert Kovacs has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Abbott. Norbert Kovacs has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Abbvie.